Bellevue Group AG Acquires 126,812 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Bellevue Group AG lifted its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 57.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 348,527 shares of the company’s stock after purchasing an additional 126,812 shares during the quarter. Bellevue Group AG owned about 0.61% of Structure Therapeutics worth $7,228,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Assetmark Inc. raised its stake in Structure Therapeutics by 39.9% during the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after buying an additional 820 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Structure Therapeutics by 29.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock worth $92,000 after purchasing an additional 994 shares during the last quarter. Good Life Advisors LLC raised its position in shares of Structure Therapeutics by 15.4% in the 2nd quarter. Good Life Advisors LLC now owns 15,000 shares of the company’s stock worth $311,000 after purchasing an additional 2,000 shares during the last quarter. National Bank of Canada FI boosted its stake in Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock worth $51,000 after purchasing an additional 2,766 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in Structure Therapeutics by 9.1% during the 2nd quarter. Bank of Montreal Can now owns 58,073 shares of the company’s stock valued at $1,224,000 after purchasing an additional 4,838 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Morgan Stanley lifted their target price on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday. Lifesci Capital raised Structure Therapeutics to a “strong-buy” rating in a research report on Monday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Wednesday, October 8th. Piper Sandler restated an “overweight” rating on shares of Structure Therapeutics in a research note on Tuesday, October 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Structure Therapeutics in a report on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $95.78.

Structure Therapeutics Trading Down 0.6%

NASDAQ:GPCR opened at $67.06 on Friday. The company has a market cap of $3.88 billion, a PE ratio of -54.97 and a beta of -1.64. The company has a 50 day simple moving average of $35.52 and a two-hundred day simple moving average of $25.79. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $13.22 and a 12 month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). Research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.